Fig. 5

CAR.CD123-NK cells exert a significant anti-leukaemia activity in an AML xenograft NGS model. A Illustration of experimental setting in which NSG mice were systemically infused with THP-1-FF-Luc.GFP cells and, at the time of leukaemia engraftment, treated with NT-T, CAR.CD123-T, NT-NK and CAR.CD123-NK cells. B Time course of in vivo bioluminescence imaging of the treated NSG mice from Day 0 (Day of effector cells infusion) to Day 50. C Graph shows bioluminescence analysis of each leukaemia-bearing mouse treated with NT-T (black line with circles), CAR.CD123-T (green line with squares), NT-NK (blue line with pentagon) and CAR.CD123-NK (red line with triangles) cells. D One hundred days probability of overall survival (OS) of leukaemia-bearing mice treated with 2 consecutive adoptive transfers of NT-T (black line with circles), CAR.CD123-T (green line with squares), NT-NK (blue line with pentagon) and CAR.CD123-NK (red line with triangles) cells. On the right bottom, the statistical analysis of 100-Day OS of leukaemia-bearing mice treated with 2 consecutive adoptive transfers of NT-T, CAR.CD123-T, NT-NK, and CAR.CD123-NK cells